Clinical trials: Dry Eye
Dry Eye Disease With Severe Keratitis
3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
The proposed 36-month Post Approval Efficacy Study (PAES) is a prospective, interventional, multicentre study to explore the long-term evolution of signs and symptoms, and occurrence of complications in Dry Eye Disease (DED)…
- Trial name
- NCT04144413
- Testing
- Open-label Ikervis, Masked Ikervis, Vehicle Comparator: Masked Vehicle
- Where
- 45 sites in Czechia, France and 5 more
- Volunteers
- 350 people
- Sponsor
- Santen SAS
Geographic Atrophy
CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)
The purpose of this study is to evaluate the safety and efficacy of 12 (every 28 days) intravitreal (IVT) injections of CLG561 as a monotherapy and in combination with LFG316 as compared to sham in subjects with geographic…
- Trial name
- NCT02515942
- Testing
- CLG561, LFG316
- Volunteers
- 114 people
- Sponsor
- Alcon Research
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye
Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease
The goal of this research is to determine if the Tangible Boost system adequately replenishes the Hydra-PEG coating on the surface of a rigid contact lens.
- Conditions
- Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
- Trial name
- NCT04313725
- Testing
- Tangible Boost
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Tangible Science
Dry Eye Syndrome
Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome
The purpose of this study was to determine if Sodium Hyaluronate, 0.18% is effective in treating the signs and symptoms of dry eye disease.
- Trial name
- NCT01382225
- Testing
- Sodium Hyaluronate Ophthalmic Solution, 0.18%, Vehicle
- Volunteers
- 1,936 people
- Sponsor
- Alcon Research
Dry Eye, Neuropathic Eye Pain
Azithromycin for Meibomian Gland Disease
This study aims to elucidate the effectiveness of oral azithromycin in treating symptomatic dry eye syndrome secondary to Meibomian gland dysfunction.
- Conditions
- Dry Eye, Neuropathic Eye Pain, Ocular Microbiome, Depression, Anxiety
- Trial name
- NCT03953118
- Testing
- Azithromycin Oral Product
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Dry Eye
Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
Study design: Phase I clinical trial, single-center, controlled, parallel group, open, randomized. Number of subjects: n = 34 evaluable subjects, 17 evaluable subjects per group (both eyes).
- Trial name
- PRO-037 (NCT04081610)
- Testing
- lagricel ofteno multidose, lagricel ofteno single dose
- Where
- Mexico
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Syndromes
A Study to Determine the Prevalence of Inflammatory Dry Eye Disease in Patients Prior to Cataract Removal
This study will evaluate the prevalence of inflammatory dry eye disease in patients prior to cataract surgery. No treatment is administered in this study.
- Trial name
- REVEAL (NCT01882413)
- Testing
- No intervention
- Where
- 6 sites in Canada
- Volunteers
- 204 people
- Sponsor
- Allergan
Dry Eye Disease
A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512
The purpose of this study is to evaluate the safety of topical ophthalmic 0.003% AR-15512 compared to its vehicle dosed twice daily (BID) in subjects with dry eye disease (DED) for 12 months.
- Trial name
- COMET-4 (NCT05493111)
- Testing
- 0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
- Where
- 10 sites in United States
- Volunteers
- 275 people
- Sponsor
- Aerie Pharmaceuticals
Meibomian Gland Dysfunction, Posterior Blepharitis
Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis
This is a Phase IV, single site, randomized, double masked, parallel control clinical trial of 60 subjects to investigate the variance of efficacy between Lotemax® and Zylet® for treatment of ocular surface inflammation due to…
- Trial name
- ZvL (NCT01456780)
- Testing
- Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Dry Eye
A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)
The purpose of this study is to evaluate the efficacy of three different concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution compared to placebo in the treatment of dry eye.
- Trial name
- NCT00926185
- Testing
- Lifitegrast
- Where
- 5 sites in United States
- Volunteers
- 230 people
- Sponsor
- Shire
Dry Eye
Acute Comfort of Lubricant Eye Drop FID 111421
To evaluate the acute comfort and blurring profile between two artificial tears products in dry eye patients
- Trial name
- NCT00673959
- Testing
- Lubricant Eye Drop FID 111421, Optive Lubricant Eye Drop
- Volunteers
- 20 people
- Sponsor
- Alcon Research
Dry Eye Syndromes
Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease
This study will evaluate the safety, efficacy, and acceptability of an eye drop formulation in subjects with dry eye disease.
- Trial name
- NCT01459588
- Testing
- Carboxymethylcellulose Based Eye Drop Formulation A, Carboxymethylcellulose Based Eye Drop Formulation B, Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Allergan
Chronic Ocular Pain
Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)
The study was designed to demonstrate the safety and efficacy of two dose concentrations of SAF312 eye drops (5 mg/mL and 15 mg/mL) in subjects with CICP persisting at least for 4 months after refractive or cataract surgery and…
- Trial name
- NCT04630158
- Testing
- SAF312
- Where
- 28 sites in United States, Japan and 1 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye
Clinical Evaluation of Systane® Gel Drops in Dry Eye Subjects
The purpose of this study is to evaluate the efficacy and safety of Systane® Gel Drops in dry eye subjects following 90 days of QID (4 times/day) dosing.
- Trial name
- NCT02380248
- Testing
- Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops
- Where
- India
- Volunteers
- 207 people
- Sponsor
- Alcon Research
Dry Eye Syndromes
Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome
Comparison of the efficacy and safety of T2750 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome
- Trial name
- NCT01568593
- Testing
- T2750, Vismed
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Laboratoires Thea
Dry Eye
Ocular Effects of Scleral Lens Wear on Dry Eye Patients
The purpose of this study is to investigate the effects of scleral contact lens wear on a DE population using coated (Hydra-PEG) and uncoated (control) lenses.
- Trial name
- NCT05079321
- Testing
- Hydra-PEG, Uncoated
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Waterloo
Dry Eye Syndromes
Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease
This study will investigate the safety, efficacy and acceptability of two new eye drop formulations compared with Refresh Tears® in patients with dry eye disease.
- Trial name
- NCT01294384
- Testing
- carboxymethylcellulose sodium based New Eye Drop Formulation 1, carboxymethylcellulose sodium based New Eye Drop Formulation 2, carboxymethylcellulose sodium based Eye Drops
- Where
- 2 sites in Australia, Canada
- Volunteers
- 305 people
- Sponsor
- Allergan
Age-related Macular Degeneration
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth…
- Trial name
- TALON (NCT04005352)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 118 sites in United States, Argentina and 18 more
- Volunteers
- 734 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Disease
Evaluation of Ocular Comfort With ISTA Tears vs Systane
To assess the comfort preference of ISTA Tears vs Systane in patients with dry eye disease (DED)
- Trial name
- NCT01650584
- Testing
- ISTA Tears, Systane
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye
Efficacy and Safety Study of FID 119515A
The purpose of this study was to compare the effect of FID 119515A to Blink® Tears on the integrity of tear film in adults with a history of dry eye in both eyes.
- Trial name
- NCT01833117
- Testing
- FID 119515A, Blink® Tears
- Volunteers
- 75 people
- Sponsor
- Alcon Research